Globus Medical (GMED) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $76.71, -2.70% vs the prior close of $78.84.
- Volume 1.94M shares, 1.3x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
GMED dips 2.7% to $76.71. Closed at $76.71, -2.70% vs the prior close of $78.84. Day range $76.49–$79.95, opened at $79.35.
GMED daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — GMED dips 2.7% to $76.71
- Closed at $76.71, -2.70% vs the prior close of $78.84. Day range $76.49–$79.95, opened at $79.35.
- Volume was 1.94M shares, 1.3x its 50-day average of 1.48M.
- Price is -2.6% vs its 50-day average ($78.72) and -8.7% vs its 200-day average ($84.05).
- 52-week range $58.32–$101.40; today's close sits at 43% of that range, 24.3% below the 52-week high.
Oct 15, 2026 — GMED jumps 3.3% to $78.84, a 1-month high
- Closed at $78.84, +3.32% vs the prior close of $76.31. Day range $77.05–$79.28, opened at $77.66.
- Volume was 1.84M shares, 1.2x its 50-day average of 1.47M.
- Price is +0.0% vs its 50-day average ($78.81) and -6.3% vs its 200-day average ($84.11).
- 52-week range $57.68–$101.40; today's close sits at 48% of that range, 22.2% below the 52-week high.
Oct 14, 2026 — GMED ends flat (-0.0%) to $76.31
- Closed at $76.31, -0.01% vs the prior close of $76.32. Day range $75.13–$76.73, opened at $76.57.
- Volume was 1.06M shares, 0.7x its 50-day average of 1.48M.
- Price is -3.2% vs its 50-day average ($78.85) and -9.3% vs its 200-day average ($84.16).
- 52-week range $56.96–$101.40; today's close sits at 44% of that range, 24.7% below the 52-week high.
Oct 13, 2026 — GMED ends flat (+0.1%) to $76.32, 3 up days in a row
- Closed at $76.32, +0.10% vs the prior close of $76.24. Day range $74.99–$76.71, opened at $76.70.
- Volume was 1.11M shares, 0.8x its 50-day average of 1.47M.
- Price is -3.3% vs its 50-day average ($78.95) and -9.4% vs its 200-day average ($84.22).
- 52-week range $56.66–$101.40; today's close sits at 44% of that range, 24.7% below the 52-week high.
- That makes 3 straight gains.
Oct 12, 2026 — GMED rises 2.1% to $76.24
- Closed at $76.24, +2.13% vs the prior close of $74.65. Day range $74.61–$76.39, opened at $74.89.
- Volume was 1.10M shares, 0.7x its 50-day average of 1.47M.
- Price is -3.6% vs its 50-day average ($79.05) and -9.5% vs its 200-day average ($84.28).
- 52-week range $56.50–$101.40; today's close sits at 44% of that range, 24.8% below the 52-week high.
Oct 9, 2026 — GMED rises 1.8% to $74.65
- Closed at $74.65, +1.80% vs the prior close of $73.33. Day range $73.68–$75.32, opened at $73.90.
- Volume was 1.08M shares, 0.7x its 50-day average of 1.47M.
- Price is -5.6% vs its 50-day average ($79.10) and -11.5% vs its 200-day average ($84.34).
- 52-week range $56.50–$101.40; today's close sits at 40% of that range, 26.4% below the 52-week high.
Oct 8, 2026 — GMED dips 0.6% to $73.33, a 6-month low, 3 down days in a row
- Closed at $73.33, -0.57% vs the prior close of $73.75. Day range $72.54–$74.27, opened at $73.48.
- Volume was 1.89M shares, 1.3x its 50-day average of 1.46M.
- Price is -7.4% vs its 50-day average ($79.22) and -13.1% vs its 200-day average ($84.41).
- 52-week range $56.50–$101.40; today's close sits at 37% of that range, 27.7% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — GMED slides 3.5% to $73.75
- Closed at $73.75, -3.51% vs the prior close of $76.43. Day range $73.26–$76.66, opened at $75.56.
- Volume was 2.47M shares, 1.7x its 50-day average of 1.43M.
- Price is -7.1% vs its 50-day average ($79.38) and -12.7% vs its 200-day average ($84.48).
- 52-week range $56.50–$101.40; today's close sits at 38% of that range, 27.3% below the 52-week high.
Oct 6, 2026 — GMED ends flat (-0.2%) to $76.43
- Closed at $76.43, -0.18% vs the prior close of $76.57. Day range $75.84–$77.66, opened at $77.01.
- Volume was 1.57M shares, 1.1x its 50-day average of 1.42M.
- Price is -3.9% vs its 50-day average ($79.51) and -9.6% vs its 200-day average ($84.55).
- 52-week range $56.50–$101.40; today's close sits at 44% of that range, 24.6% below the 52-week high.
Oct 5, 2026 — GMED rises 1.3% to $76.57
- Closed at $76.57, +1.28% vs the prior close of $75.60. Day range $75.03–$77.17, opened at $75.60.
- Volume was 1.61M shares, 1.1x its 50-day average of 1.43M.
- Price is -3.7% vs its 50-day average ($79.55) and -9.5% vs its 200-day average ($84.59).
- 52-week range $56.50–$101.40; today's close sits at 45% of that range, 24.5% below the 52-week high.
Oct 2, 2026 — GMED rises 1.6% to $75.60
- Closed at $75.60, +1.60% vs the prior close of $74.41. Day range $74.22–$76.16, opened at $75.00.
- Volume was 1.31M shares, 0.9x its 50-day average of 1.42M.
- Price is -5.0% vs its 50-day average ($79.55) and -10.7% vs its 200-day average ($84.64).
- 52-week range $56.50–$101.40; today's close sits at 43% of that range, 25.4% below the 52-week high.
GMED latest news & SEC filings
Every SEC filing by or about GMED in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 16, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Tobin James R converted options/RSUs into 15,000 shares at $53.75 (≈$806.25K) on Sep 15, 2026; now holds 15,000
- Tobin James R converted options/RSUs into 15,000 shares at $63.68 (≈$955.20K) on Sep 15, 2026; now holds 30,000
- Tobin James R sold 30,000 shares at $74.58 (≈$2.24M) on Sep 15, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 15, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 19, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Zarrilli Stephen T sold 25,000 shares at $87.04 (≈$2.18M) on Aug 18, 2026
- Zarrilli Stephen T sold 25,000 shares at $87.04 (≈$2.18M) on Aug 18, 2026
- Zarrilli Stephen T sold 25,000 shares at $87.04 (≈$2.18M) on Aug 18, 2026
- Zarrilli Stephen T sold 25,000 shares at $87.04 (≈$2.18M) on Aug 18, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 18, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $789.61M (prior year $745.34M) (+5.9% vs Jun 30, 2025)
- Net income: $151.57M (prior year $202.85M) (-25.3% vs Jun 30, 2025)
- Diluted EPS: $1.10 (prior year $1.49) (-26.2% vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 28, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Things to know before you trade GMED
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Feb 24, 2026, Jan 7, 2026. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.22% (largest 3.5%).
- Liquidity: about 1.54M shares (≈$118.12M) trade per day on average.
- 52-week position: $76.71 vs a range of $58.32–$101.40 (43% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: James R Tobin sold 30,000 shares on Sep 15, 2026.
- Latest filings: 10-Q Aug 6, 2026; 8-K Aug 6, 2026; 8-K Jun 4, 2026.
- Share count: 134.26M shares outstanding (Aug 4, 2026), -0.6% vs a year earlier.
- Listing: NYSE · industry: Surgical & Medical Instruments & Apparatus.
GMED market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 79.35 | 79.95 | 76.49 | 76.71 | 1.94M |
| Oct 15, 2026 | 77.66 | 79.28 | 77.05 | 78.84 | 1.84M |
| Oct 14, 2026 | 76.57 | 76.73 | 75.13 | 76.31 | 1.06M |
| Oct 13, 2026 | 76.70 | 76.71 | 74.99 | 76.32 | 1.11M |
| Oct 12, 2026 | 74.89 | 76.39 | 74.61 | 76.24 | 1.10M |
| Oct 9, 2026 | 73.90 | 75.32 | 73.68 | 74.65 | 1.08M |
| Oct 8, 2026 | 73.48 | 74.27 | 72.54 | 73.33 | 1.89M |
| Oct 7, 2026 | 75.56 | 76.66 | 73.26 | 73.75 | 2.47M |
| Oct 6, 2026 | 77.01 | 77.66 | 75.84 | 76.43 | 1.57M |
| Oct 5, 2026 | 75.60 | 77.17 | 75.03 | 76.57 | 1.61M |
| Oct 2, 2026 | 75.00 | 76.16 | 74.22 | 75.60 | 1.31M |
| Oct 1, 2026 | 74.61 | 75.26 | 74.18 | 74.41 | 1.44M |
| Sep 30, 2026 | 75.42 | 75.50 | 74.57 | 74.90 | 1.25M |
| Sep 29, 2026 | 74.62 | 75.78 | 73.80 | 75.69 | 1.58M |
| Sep 28, 2026 | 74.25 | 75.15 | 73.67 | 74.78 | 1.73M |
| Sep 25, 2026 | 74.53 | 75.10 | 73.69 | 74.52 | 1.56M |
| Sep 24, 2026 | 74.21 | 74.99 | 73.70 | 74.27 | 1.63M |
| Sep 23, 2026 | 74.95 | 75.34 | 73.75 | 73.96 | 1.46M |
| Sep 22, 2026 | 74.99 | 75.73 | 74.37 | 75.19 | 1.93M |
| Sep 21, 2026 | 74.00 | 74.41 | 73.17 | 74.29 | 1.25M |
About Globus Medical
Globus Medical (GMED) is listed on the NYSE and classified by the SEC under “Surgical & Medical Instruments & Apparatus”. Its business address is in AUDUBON, PA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1237831.
GMED board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| David D Davidar | Director | Jul 28, 2026 |
| John A Deford | Director | Jan 23, 2026 |
| Robert Andrew Douglas | Director | Jan 23, 2026 |
| Dan Lemaitre | Director | Jan 23, 2026 |
| Leslie V Norwalk | Director | Jan 23, 2026 |
| David C Paul | Executive Chairman | Jan 23, 2026 |
| Keith W Pfeil | President, CEO | Jan 23, 2026 |
| Ann D Rhoads | Director | Jun 8, 2026 |
| James R Tobin | Director | Sep 16, 2026 |
| Dan Wolterman | Director | Jan 23, 2026 |
| Stephen T Zarrilli | Director | Aug 19, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Kelly Huller | EVP, GC, Corporate Secretary | Feb 27, 2026 |
| Kyle Kline | Senior Vice President, CFO | Jan 23, 2026 |
| David C Paul | Executive Chairman | Jan 23, 2026 |
| Keith W Pfeil | President, CEO | Jan 23, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 15, 2026 | James R Tobin | Sale | 30,000 | $74.58 |
| Sep 15, 2026 | James R Tobin | Sale | 30,000 | $74.58 |
| Sep 15, 2026 | James R Tobin | Sale | 30,000 | $74.58 |
| Sep 15, 2026 | James R Tobin | Sale | 30,000 | $74.58 |
| Aug 18, 2026 | Stephen T Zarrilli | Sale | 25,000 | $87.04 |
| Aug 18, 2026 | Stephen T Zarrilli | Sale | 25,000 | $87.04 |
| Aug 18, 2026 | Stephen T Zarrilli | Sale | 25,000 | $87.04 |
| Aug 18, 2026 | Stephen T Zarrilli | Sale | 25,000 | $87.04 |
| Jun 5, 2026 | David D Davidar | Sale | 25,000 | $80.76 |
| Jun 5, 2026 | David D Davidar | Sale | 25,000 | $80.76 |
| Jun 5, 2026 | David D Davidar | Sale | 25,000 | $80.76 |
| Jun 5, 2026 | David D Davidar | Sale | 25,000 | $80.76 |
| Feb 25, 2026 | Kelly Huller | Sale | 20,000 | $94.50 |
| Feb 25, 2026 | Kelly Huller | Sale | 20,000 | $94.50 |
| Feb 25, 2026 | Kelly Huller | Sale | 20,000 | $94.50 |
GMED financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $2.94B | $537.87M | 3.92 | $753.45M |
| Dec 31, 2024 | $2.52B | $102.98M | 0.75 | $520.64M |
| Dec 31, 2023 | $1.57B | $122.87M | 1.07 | $243.50M |
| Dec 31, 2022 | $1.02B | $190.17M | 1.85 | $178.47M |
| Dec 31, 2021 | $958.10M | $149.19M | 1.44 | $276.27M |
Latest balance sheet: total assets $5.49B, total liabilities $719.65M, cash $507.75M (as of Jun 30, 2026).
GMED earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $81.08 |
| May 7, 2026 | 8-K Item 2.02 (results) | $85.07 |
| Feb 24, 2026 | 8-K Item 2.02 (results) | $91.88 |
| Jan 7, 2026 | 8-K Item 2.02 (results) | $90.54 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $61.71 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $54.07 |
| Jul 21, 2025 | 8-K Item 2.02 (results) | $51.89 |
| May 8, 2025 | 8-K Item 2.02 (results) | $72.46 |
| Feb 20, 2025 | 8-K Item 2.02 (results) | $84.12 |
| Jan 8, 2025 | 8-K Item 2.02 (results) | $86.55 |
| Nov 5, 2024 | 8-K Item 2.02 (results) | $75.58 |
| Aug 6, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Surgical & Medical Instruments & Apparatus
Boston Scientific (BSX)Stryker (SYK)3M (MMM)Dexcom (DXCM)Medline (MDLN)Becton Dickinson (BDX)MiniMed (MMED)Resmed (RMD)Insulet (PODD)West Pharmaceutical Services (WST)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on GMED
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.